Sprint: How Can DTx Companies De-Risk Combination Products for Better Pharma Adoption? (Part 2)

Pharma companies are not risk takers, and adding a DTx to their products can be seen as a threat rather than a value-add. Developing an effective drug-DTx combination product requires making the right choices from the early days to reduce risks throughout the journey and ensure that the benefits outweigh the risks. But how can DTx companies de-risk combination products for better pharma adoption? What are the main obstacles DTx companies face when dealing with pharma? In this sprint, we will break this down into 5 key challenges and agree on 5 key recommendations to overcome them. At the end of the session, HealthXL will put together an output with the learnings from the group. 

 

Some of the major challenges we may tackle (these are some examples - the group will agree on the problems they want to address): 

We would like to remind you that our meetings are small and intimate sessions with a limited number of seats available, therefore we rely on your attendance and participation to ensure a high quality and valuable meeting for all. If you are confirmed for this meeting we ask if you can please ensure your attendance on the day.